MedTrace Logo

Ticagrelor in Remote Ischemic Preconditioning Study

NCT04174261 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2019-11-22

No results posted yet for this study

Summary

Remote ischemic preconditioning (RIPC) reduces periprocedural myocardial injury (PMI) after percutaneous coronary intervention (PCI) through various pathways, including an adenosine-triggered pathway. Ticagrelor inhibits adenosine uptake, thus may potentiate the effects of RIPC.

This randomized trial tested the hypothesis that ticagrelor potentiates the effect of RIPC and reduces PMI, as assessed by post-procedural troponin release

Conditions

  • Periprocedural Myocardial Infarction

Interventions

DRUG

Ticagrelor

Preprocedural ticagrelor loading and standard dose thereafter

PROCEDURE

Remote Ischemic Preconditioning

Preprocedural remote ischemic preconditioning on the non-dominant arm

DRUG

Clopidogrel

Preprocedural clopidogrel loading and standard dose thereafter

Sponsors & Collaborators

  • Hellenic Society of Interventional Cardiology

    lead OTHER

Principal Investigators

  • Apostolos Katsivas · Head Cardiology Department, Athens Red Cross Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-29
Primary Completion
2017-12-18
Completion
2018-01-17

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04174261 on ClinicalTrials.gov